What is Repatha?
As of October 11th, Rubraca (Rucaparib) has been approved for NHS use by NICE in its final draft guidance (NICE, 2019). The drug, developed by the University of Newcastle, will benefit women with...
The pharmaceutical pricing landscape is by the most convoluted system and the main culprit of this is the USA. The pricing structure of the pharmaceuticals is by no means transparent and requires...
Black Swan Analysis had a poster accepted at ISPOR USA 2019 in New Orleans titled “Impact of international reference pricing on five products in the USA”.
The Rx Price IndexTM is an online database that lists all licensed available pharmaceutical products in the European Union and other Markets. By displaying pricing information from June 2015 to the...
The high cost of prescription drugs has been a major issue in the U.S, for decades. This is supportive of the fact the U.S spends twice as much on prescription drugs as other comparable western...
When it comes to making pharmaceutical forecasts and market access analysis, data quality can make or break the process. Launching a new product in multiple markets beyond your own requires a...
Pharmaceutical prices are known to experience big fluctuations over short time frames. A dynamic pricing strategy should take into account the different factors that influence buying decisions, in...
